Abstract:Idiopathic pulmonary fibrosis (IPF) seriously threatens human life and health, and no curative therapy is available at present. Nintedanib is the first agent approved by the US Food and Drug Administration (FDA) in order to treat IPF; however, its mechanism of inhibition of IPF is still elusive. According to recent studies, nintedanib is a potent inhibitor. It can antagonize platelet-derived growth factor (PDGF), basic fibroblast growth factor (b-FGF), vascular endothelial growth factor (VEGF), etc, to inhibit pulmonary fibrosis. Whether there are other signaling pathways involved in IPF remains unknown. This study focused on investigating the therapeutic efficacy of nintedanib in bleomycin-mediated pulmonary fibrosis (PF) mice through PI3K/Akt/mTOR pathway. Following the induction of pulmonary fibrosis in C57 mice through bleomycin (BLM) administration, the mice were randomized into five groups: (1) the normal control group, (2) the BLM model control group, (3) the low-dose Nintedanib administration model group, (4) the medium-dose nintedanib administration model group, and (5) the high-dose nintedanib administration model group. For lung tissues, morphological changes were found by HE staining and Masson staining, ELISA method was used to detect inflammatory factors, alkaline water method to estimate collagen content, and western blotting for protein levels. TUNEL staining and immunofluorescence methods were used to analyze the effect of nintedanib on lung tissue and the impacts and underlying mechanisms of bleomycin-induced pulmonary fibrosis. After 28 days, bleomycin-treated mice developed significant pulmonary fibrosis. Relative to bleomycin-treated mice, nintedanib-treated mice had markedly reduced degrees of PF. In addition, nintedanib showed lung-protective effects by up-regulating antioxidant levels, down-regulating inflammatory protein expression, and reducing collagen accumulation. We demonstrated that nintedanib ameliorated bleomycin-induced lung injury by inhibiting the P13K/Akt/mTOR pathway as well as apoptosis. In addition, significant improvement in pulmonary fibrosis was seen after nintedanib (30/60/120 mg/kg body weight/day) treatment through a dose-dependent way. Histopathological results further corroborated the effect of nintedanib treatment on remarkably attenuating bleomycin-mediated mouse lung injury. According to our findings, nintedanib restores the antioxidant system, suppresses pro-inflammatory factors, and inhibits apoptosis. Nintedanib can reduce bleomycin-induced inflammation by downregulating PI3K/Akt/mTOR pathway, PF, and oxidative stress (OS).

Reduced tracheal stenosing effect of nintedanib in a patient with scarred posttraumatic tracheal stenosis and airflow limitation

Inhalation of Itraconazole Mitigates Bleomycin-Induced Lung Fibrosis Via Regulating SPP1 and C3 Signaling Pathway Pivotal in the Interaction Between Phagocytic Macrophages and Diseased Fibroblasts

Nintedanib: A Review in Fibrotic Interstitial Lung Diseases

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases

Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Intratracheal therapy using nintedanib amorphous particles in murine pulmonary fibrosis

Effect of nintedanib on non-small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review

Nintedanib and symptoms of fibrotic lung disease: a glimmer of hope for patients living with pulmonary fibrosis

Nintedanib reduces alloimmune-induced chronic airway changes in murine tracheal allografts

Nintedanib in Idiopathic Pulmonary Fibrosis: Tolerability and Safety in a Real Life Experience in a Single Centre in Patients also Treated with Oral Anticoagulant Therapy

Nintedanib: A Novel Therapeutic Approach for Idiopathic Pulmonary Fibrosis

Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience

Novel Mechanisms for the Antifibrotic Action of Nintedanib

The safety of nintedanib for the treatment of interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials

Comparison of the clinical effectiveness of nintedanib at full and reduced dosage in patients with idiopathic pulmonary fibrosis and progressive non-idiopathic fibrosis

Endoscopic Airway Stenting for Tracheobronchial Stenosis and Tracheoesophageal Fistula

Safety of Nintedanib in a Patient with Chronic Pulmonary Fibrosis and Kidney Disease

Nintedanib in IPF: Post hoc Analysis of the Italian FIBRONET Observational Study

Nintedanib Ameliorates Bleomycin-Induced Pulmonary Fibrosis, Inflammation, Apoptosis, and Oxidative Stress by Modulating PI3K/Akt/mTOR Pathway in Mice

Cardiovascular safety of the tyrosine kinase inhibitor nintedanib

Transcriptomic analysis reveals lipid metabolism and macrophage involvement associated with nintedanib treatment in a rat bleomycin model